Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

ROCHE HOLDING LTD. (ROG)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Roche Holding Ltd. : UPCOMING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Roche Holding AG and Reminds Investors with Losses to Contact the Firm

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/17/2017 | 10:03pm CET

IRVINE, CA / ACCESSWIRE / July 17, 2017 / Khang & Khang LLP (the "Firm") announces a securities class action lawsuit against Roche Holding AG ("Roche Holding" or the "Company") (OTCQX: RHHBY). Investors, who purchased or otherwise acquired shares from March 2, 2017 through June 5, 2017, inclusive (the "Class Period"), are encouraged to contact the Firm before the August 7, 2017 lead plaintiff motion deadline.

If you purchased shares of Roche Holding during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone at (949) 419-3834, or by e-mail at [email protected].

There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may also choose to take no action and remain a passive class member.

According to the Complaint, throughout the Class Period, Roche Holding issued materially false and misleading statements and/or failed to disclose material information, specifically that the combination of the Company's breast cancer drug, Perjeta, and its older treatment, Herceptin, is only marginally more effective than Herceptin alone in preventing breast cancer, and has a higher rate of side effects. Following this news, Roche Holding's stock price dropped materially, causing investors harm according to the Complaint.

If you want to learn more about this lawsuit, or if you have questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or by e-mail at [email protected].

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
[email protected]

SOURCE: Khang & Khang LLP


© Accesswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ROCHE HOLDING LTD.
02/19ROCHE : Prothena Reports Fourth Quarter and Full Year 2017 Financial Results, an..
AQ
02/19ROCHE : Clifton sees increase in its tax base
AQ
02/19AstraZeneca's immunotherapy drug wins key lung cancer approval
RE
02/18ROCHE : Ex-Googlers Strike Startup Gold Again With $1.9 Billion Sale
AQ
02/16ROCHE : Diagnostics recognizes Wisconsin Diagnostic Laboratories as Roche Molecu..
AQ
02/16ROCHE : LGC Maine Standards Announces VALIDATE Procalcitonin Kit for Easier Line..
AQ
02/16ROCHE : Slump ends and city sees tax base increase
AQ
02/16ROCHE : acquiring Flatiron for $1.9B
AQ
02/16ROCHE : Ex-Googlers strike startup gold -- again -- with $1.9 billion sale to dr..
AQ
02/16ROCHE : LGC Maine Standards Announces VALIDATE® Procalcitonin Kit for Easier Lin..
AQ
More news
News from SeekingAlpha
02/16Celgene's Otezla-Colitis Story; Implications For Other Biotechs 
02/16Roche To Acquire Flatiron Health For $1.9 Billion 
02/16WALL STREET BREAKFAST : Major Recovery For Wall Street 
02/16Key events next week - healthcare 
02/16'Intense' flu season to continue 
Financials ( CHF)
Sales 2018 55 357 M
EBIT 2018 18 835 M
Net income 2018 12 211 M
Debt 2018 4 557 M
Yield 2018 3,96%
P/E ratio 2018 15,46
P/E ratio 2019 14,86
EV / Sales 2018 3,57x
EV / Sales 2019 3,42x
Capitalization 193 B
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 268  CHF
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-9.37%207 160
JOHNSON & JOHNSON-7.19%357 710
NOVARTIS-3.37%224 785
PFIZER-2.84%216 135
MERCK AND COMPANY-0.50%153 359
AMGEN3.23%133 241